Heart valve repair may unlock better drug dosing for heart failure

NCT ID NCT06702527

Terminated Knowledge-focused Sponsor: Institut für Pharmakologie und Präventive Medizin Source: ClinicalTrials.gov ↗

First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This registry tracks people with severe functional mitral regurgitation and heart failure who undergo a minimally invasive mitral valve repair called M-TEER. The goal is to see whether the repair allows patients to tolerate higher, guideline-recommended doses of heart failure medications that often cause side effects. Researchers will compare hospitalizations and symptoms before and after the procedure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Mitral transcatheter edge-to-edge repair (M-TEER) with the PASCAL system
What this could lead to: If the procedure helps patients tolerate higher doses of heart failure medications, it could point toward a way to improve drug therapy and reduce hospitalizations.
What could go wrong: This is a small pilot registry with only 9 participants, so results may not apply broadly. The study is observational, meaning it cannot prove cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart failure mitral valve insufficiency

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART FAILURE M-TEER MITRAL REGURGITATION FUNCTIONAL

Contacts and locations

Locations

Cellitinnen_Krankenhaus St. Vinzenz Köln

Cologne, 50733, Germany
Krh der Barmherzigen Brüder Trier

Trier, 54292, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.